CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 14, 2016, Pages 3850-3854

  Clark, Andrew J ^a   Wiley, Devin T ^a   Zuckerman, Jonathan E ^a,b   Webster, Paul ^c   Chao, Joseph ^d   Lin, James ^d   Yen, Yun ^e   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OAK CREST INSTITUTE OF SCIENCE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clinical trial; Gastric cancer; Nanomedicine; Nanoparticles; Tumor targeting

Indexed keywords

CAMPTOTHECIN; CARBONATE DEHYDRATASE IX; CRLX 101; DNA TOPOISOMERASE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLODEXTRIN; IT-101; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE MICROSCOPY; GASTROESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; ANIMAL; DRUG SCREENING; ENDOSCOPY; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMARKERS, TUMOR; CAMPTOTHECIN; CARBONIC ANHYDRASE IX; CELL LINE, TUMOR; CYCLODEXTRINS; DNA TOPOISOMERASES, TYPE I; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; HUMANS; MICE; NANOPARTICLES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962711424     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1603018113     Document Type: Article

References (21)

1. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771-782.
2. Harrington KJ, et al. (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7(2):243-254.
3. Koukourakis MI, et al. (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17(11):3512-3521.
4. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
5. Eliasof S, et al. (2013) Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 110(37):15127-15132.
6. Weiss GJ, et al. (2013) First-in-human phase 1/2a trial of CRLX101, a cyclodextrin containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 31(4):986-1000.
7. Pham E, et al. (2015) Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res 21(4):808-818.
8. Schluep T, et al. (2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci USA 106(27):11394-11399.
9. Kaluz S, Kaluzová M, Liao S-Y, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2):162-172.
10. Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 91:3-6.
11. McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27(1):15-26.
12. Araya M, et al. (1997) Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol 65(4):232-236.
13. Cheng J, Khin KT, Jensen GS, Liu A, Davis ME (2003) Synthesis of linear, β-cyclodextrinbased polymers and their camptothecin conjugates. Bioconjug Chem 14(5):1007-1017.
14. Ng TSC, et al. (2013) Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19(9):2518-2527.
15. Gaur S, et al. (2014) Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine (Lond) 10(7):1477-1486.
16. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P (1997) Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 272(39):24159-24164.
17. Fu Q, Kim SW, Chen HX, Grill S, Cheng YC (1999) Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol Pharmacol 55(4):677-683.
18. Lin C-P, Ban Y, Lyu YL, Liu LF (2009) Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem 284(41):28084-28092.
19. Zhang H-F, et al. (2004) Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res 64(3):1114-1121.
20. Desai SD, et al. (2003) Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 23(7):2341-2350.
21. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.